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Background: Blood levels of immune markers have been proposed to discriminate
patients with Parkinson’s disease (PD) from controls. However, differences between
clinical PD subgroups regarding these markers still need to be identified.
Objective: To investigate whether clinical phenotypes can be predicted by the
assessment of immune marker profiles in the serum of PD patients.
Methods: Phenotypes of clinical PD from Tübingen, Germany (n = 145) and Toronto,
Canada (n = 90) were defined regarding clinical subtype, disease onset, severity, and
progression as well as presence of cognitive and/or autonomic dysfunction. A panel of
serum immune markers was assessed using principal component analysis (PCA) and
regression models to define the marker(s) that were associated with clinical phenotypes
after adjusting for potential confounders. Findings of both centers were compared for
validation. Further, a [18F] FEPPA-PET was performed in a group of patients with high and
low values of candidate markers for the assessment of in vivo brain microglial activation.
Results: Overall, serum immune markers did not cluster to define a
pro/anti-inflammatory profile in PCA. Out of 25 markers only IL-12p40 showed a
trend to discriminate between PD subgroups in both cohorts which could not be
replicated by [18F] FEPPA-PET.
Conclusions: Assessment of cytokines in serum does not reliably differentiate clinical
PD subtypes. Accompanying subtype-irrelevant inflammation in PD, dual activity, and
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lack of specificity of the immune markers, the complex function of microglia, probable
effects of treatment, disease stage, and progression on inflammation as well as
current technical limitations may limit the usefulness of serum immune markers for the
differentiation of subtypes.
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INTRODUCTION
Parkinson’s disease (PD) is one the most frequent movement
disorders affecting about 2–3% of the aging population (1).
It has been estimated that the number of people with PD
will double by 2030, indicating a progressive increase in the
socio-economic burden in the near future (1). For this reason,
understanding the underlying neurodegeneration is vital and
the development of disease modifying therapies is urgently
needed.
The pathological process which eventually leads to both
a progressive loss of dopaminergic neurons of the substantia
nigra and more widespread neurodegeneration in PD has been
associated with neuronal inflammation (1, 2). It has been
shown that accumulation of extracellular alpha-synuclein (α-
syn) facilitates microglia activation, which further promotes
production of immune markers, nitric oxide, and reactive
oxygen species. It is proposed that this process may lead
to nigral cell death. Within this context, pro-inflammatory
cytokines produced by the microglia are responsible for
the activation of the neighboring inactive glial cells and
thus magnify the inflammation. In addition they attach
to surface cytokine receptors of the dopaminergic cells
and trigger apoptosis (3). This mechanism may provoke
protein misfolding and thus create a vicious cycle (1).
Evidence for inflammation has been demonstrated in PD
animal models (4) as well as in PD patients in genetic (5,
6), imaging (7), CSF (8, 9), and postmortem studies (10,
11).
PD shows considerable variability with regard to age
of onset, clinical manifestations, and disease progression
which may indicate pathophysiological heterogeneity. The
extent that inflammatory processes differ and potentially
contribute to clinical PD subtypes has not been elucidated.
Detection of a clinical PD phenotype that associates with an
inflammatory profile would be critical in terms of outlining
the contribution of the immunologic mechanisms to the
underlying pathology, understanding the diversity in issues such
as drug-response, or disease progression as well as formulating
disease modifying strategies. For this reason, we set out to
determine the clinical phenotype that correlates with the
presence or absence of an inflammatory profile by extensive
clinical phenotyping of PD patients and exploratory analysis
of inflammatory markers. The results were validated by the
assessment of a separate PD cohort and further evaluated
by assessing microglial activation in vivo using [18F] FEPPA-
PET.
MATERIALS AND METHODS
The current study has been designed as a collaborative
project between the German Center for Neurodegenerative
Diseases (DZNE), Tübingen, Germany and the University Health
Network, Toronto, Canada which was supported by the Centers
of Excellence in Neurodegeneration (CoEN) initiative.
Study Design
In this cross-sectional study, two separate prospectively assessed
cohorts of PD patients from the centers of Tübingen and Toronto
were analyzed independently. In each center, patients were
grouped according to their clinical phenotypes (see methods
below) and then compared with regard to serum inflammatory
markers in order to define a clinical PD phenotype associated
with inflammation. Then, the findings of both centers were
compared for validation. In case of an agreement between two
centers regarding the inflammatory markers that differ between
clinical phenotypes, [18F] FEPPA-PET imaging was subsequently
performed on a subset of patients to further validate the relevance
of the inflammatory marker.
The study was approved by the ethics committees of the
Medical Faculties of the University of Tübingen and the
University Health Network, Toronto. All procedures were in
accordance with the Declaration of Helsinki and a written
informed consent was obtained from all participants.
Patients and Clinical Assessments
Participants older than 40 years fulfilling the criteria for
idiopathic PD according to the UK Brain Bank Criteria were
recruited from the neurology department of University Hospital
of Tübingen, Germany, and from the Morton and Gloria
Shulman Movement Disorders Clinic of Toronto Western
Hospital, Toronto, Canada. Demographic data and detailed
PD history including disease onset and duration, medication,
presence of wearing off or motor fluctuations, and accompanying
non-motor symptoms were collected. Motor performance in
the “on” medication state and the disease severity were
assessed by the Movement Disorders Society-Unified Parkinson’s
Disease Rating Scale (MDS-UPDRS) part-III and Hoehn and
Yahr Scale (H&Y), respectively. Cognitive performance and
autonomic dysfunction were assessed using the Montreal
Cognitive Assessment (MoCa) and by Scales for Outcomes
in Parkinson’s disease—Autonomic (SCOPA-AUT), respectively.
Patients with a C-reactive protein (CRP) value above 1.0 mg/dl
were excluded from the study based on the assumption that these
individuals may have an acute infection that could influence
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TABLE 1 | Methods of comparison for PD subtypes (n for Tübingen/Toronto cohort).
Method-113 n Method-2 n Method-315 n Method-412,14 n
Young onset 31/23 Young onset and slow progression 45/31 Benign motor 37/16 Benign motor 50/35
Non-tremor dominant 44/20 Late onset and fast progression 38/17 Benign motor with
cognitive/autonomic impairment
26/22 Benign motor with cognitive
impairment
15/14
Tremor dominant 24/19 – Poor motor with
cognitive/autonomic impairment
56/12 Poor motor with cognitive
impairment
37/15
Rapid progression 32/8 – – –
the levels of the collected inflammation markers. All included
PD patients were categorized into different groups with regard
to their disease onset, severity or progression rate, autonomic,
and cognitive status. Based on the previously published cluster
analyses defining PD subtypes (12–15), four different methods
of subtype classification were constructed. Each method resulted
in 2–4 groups with each group representing a clinically
defined PD subtype (Table 1). Within these subtypes, “young
onset” was defined by an age of onset of <55 or <60
years in method 1 and 2, respectively. Motor subtyping
(tremor dominant or non-tremor dominant) of the groups
was selected by evaluating the tremor and postural instability
and gait disorder (PIGD) scores of MDS-UPDRS part-III.
Disease progression was defined by dividing the MDS-UPDRS
part-III scores by disease duration. Cognitive or autonomic
impairment were defined by Montreal Cognitive Assessment
(MoCA) score lower than 26 and Scales for Outcomes in
Parkinson’s Disease-Autonomic (SCOPA-AUT) equal to or lower
than 16, respectively. The details of the group definitions are
explained in the Supplementary Table 1.
Biomaterial Collection
The following panel of immune markers composed of pro- or
anti-inflammatory cytokines as well as neuroprotective trophic
factors were assessed from the blood samples of the PD patients:
TNF-α, TNF-β, IL-1α, IL-2, IL-3, IL-4, IL-5, IL-7, IL-8, IL-10,
IL-12p40, IL-12p70, IL-13, IL-15, IL-16, IL-18, Brain-derived
neurotrophic factor (BDNF), Epithelial Neutrophil Activating
Peptide (ENA78), granulocyte-macrophage colony-stimulating
factor (GM-CSF), lymphotactin, macrophage-derived
chemokine (MDC), macrophage inflammatory protein-1β
(MIP-1β), monocyte chemotactic protein-1 (MCP-1), stem
cell factor (SCF), thrombopoetin (TPO). In both centers,
storing and analyses of biomaterial were performed by means
of standard operating procedures using the kit components
of the multiplexed immunoassay by Myriad RBM, Austin,
TX, USA. Blood samples of Toronto were obtained according
to the protocol and were sent frozen to Tübingen for the
analyses. The Tübingen samples were also frozen before
the analysis in order to allow the comparability. Analysis of
the serum inflammatory marker levels was performed using
the Luminex 100/200 instrument and data were interpreted
using the software developed and provided by Myriad RBM.
Details of the serum inflammatory marker analysis are given
elsewhere (16).
[18F] FEPPA-PET Imaging
Assessment of the in vivo brain microglial activation using a
[18F] FEPPA-PET imaging was planned as a further validation
step given that immune markers that discriminate PD groups
were detected in both cohorts. A subgroup of patients from
the Toronto cohort that underwent [18F] FEPPA-PET to assess
microglial activation were categorized according to values of
the cytokines of interest being lower or higher than the 50th
percentile of the entire group undergoing PET imaging. [18F]
FEPPA-PET images were preprocessed and region of interests
(ROI) were automatically generated using in-house software,
ROMI (17). In brief, ROMI fits a standard template of ROIs to
an individual proton density (PD)-weighted MR image based on
the probability of white matter, gray matter, and cerebrospinal
fluid. The individual MR images were then co-registered to each
summed [18F] FEPPA-PET image using the normalized mutual
information algorithm so that individual refined ROI template
can be transferred to the PET image space to generate the
time activity curve for each ROI. Our a priori ROIs included
cortical as well as subcortical brain regions such as frontal
and temporal lobes, cingulate cortex, occipital lobe, insula,
cerebellum, thalamus, and striatum. Total distribution volume
(VT), of the radioligand concentration in the ROI was measured
taking into consideration rs6791 polymorphism binding affinity.
The effect of age on the tissue volume was taken into account
by partial volume effect correction (PVEC) method. PET scans
were obtained with a high resolution PET/CT, Siemens-Biograph
HiRez XVI (Siemens Molecular Imaging, Knoxville, TN, U.S.A.).
Statistics
The collected serum inflammatory markers were compared
between the groups of eachmethod with an exploratory approach
in both cohorts. Statistical analyses were designed in two steps.
First, a principal component analysis (PCA) was performed in
the Tübingen (main) cohort with a bigger sample size to identify
the cytokines that form a pro- or anti-inflammatory immune
profile (factor) that could discriminate groups of PD. As the data
could not be reduced to factors which convincingly represent
the marker profiles (see results), binomial (for Method-2) and
multinomial logistic regression analyses (For Methods-1,3, and
4) were performed for each immune marker in the Tübingen
and the Toronto cohort in order to explore the predictive effect
of an individual immune marker. Subtype was defined as the
dependent variable, and the immune marker as the predictor
variable with age, sex, disease duration or levodopa equivalent
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TABLE 2 | Demographic characteristics of both cohorts.
Tübingen (n = 145) Toronto (n = 90)
Age [years], mean (SD) 67 (9) 62 (9)
Male sex [%] 66 70
Disease duration [years], mean (SD) 6.5 (4.0) 7.7 (4.5)
H&Y Stage (0-5), mean 2.3 1.8
LEDD [mg/day], mean (SD) 626 (407) 539 (482)
MDS-UPDRS part-III, mean (SD) 28.4 (12.5) 21.1 (10.3)
MoCA, mean (SD) 26 (3.3) 26.1 (2.6)
SCOPA-AUT, mean (SD) 14.3 (7.8) 13.4 (7)
H&Y, Hoehn & Yahr; LEDD, Levodopa equivalent daily dose, MDS-UPDRS, Movement
Disorders Society - Unified Parkinson’s Disease Rating Scale; MoCA, Montreal Cognitive
Assessment; SCOPA-AUT, Scales for Outcomes in Parkinson’s Disease - Autonomic.
daily dose (LEDD) as covariates which were added to the model
according to the group definition. For example, in Method-2,
age, and disease duration were not added to the model since the
groups were defined according to these variables. Some cytokines
were dichotomized at the median value when the data did not fit
into the regression model.
As 13 group comparisons were performed for each immune
marker (6 group comparisons for method-1, one for 2, and
three for method-3 and 4), alpha value was corrected as p <
0.05/13 = 0.0038 for each cytokine (18). A trend in the data
was defined as p < 0.05. The results from both cohorts were
compared in order to see whether the effect from the Tübingen
cohort (main cohort with a larger sample size) was verified by
the second (Toronto) cohort. Inclusion of a second cohort in the
study for the confirmation of the results was performed to reduce
the risk of type-1 error, and only significant results from both
centers were considered definitive. For the [18F] FEPPA-PET
two-group analysis an independent samples t-test was performed
also corrected for multiple comparison. SPSS Statistics 22.0.0
(SPSS Ltd., Chicago IL) was used for statistical analyses.
RESULTS
A total of 145 PD patients from Tübingen and 90 from Toronto
were included in the analysis. 14 patients were excluded due to
elevated CRP. Demographic data are shown in Table 2. IL-12p70
and GM-CSF from Toronto, and IL-2 and lymphotactin from
both cohorts were excluded since more than 95% of patients had
cytokine levels below analytical limit.
Principal Component Analysis (PCA)
In the Tübingen cohort, a PCA was conducted on serum
inflammatory markers with oblique (related) rotation (oblimin)
and elimination of factor loadings <0.4. The Kaiser–Meyer–
Olkin measure of sampling adequacy was 0.81, verifying the
adequacy of the sample size for the analysis. Bartlett’s test
of sphericity [chi-square(253) = 2125.5, p < 0.001] indicated
that correlations between items were sufficiently large for
PCA. Six components had eigenvalues over Kaiser’s criterion
of 1 and in combination explained 67% of the variance
(Supplementary Table 2). It was found that Factor-1, which has
the highest loading (28%), included pro-inflammatory cytokines
as well as IL-13 which is an anti-inflammatory cytokine. Likewise,
Factor 5 included both pro- (IL-15) and anti-inflammatory (IL-
4, IL-10) cytokines. According to the markers that gather on
the same factors, a clear separation between pro- and anti-
inflammatory marker profiles could not be achieved with PCA
(Figure 1, Supplementary Table 2).
Logistic Regression Analyses
In the Tübingen cohort, IL-1α and IL-3 (at median), and in
Toronto cohort IL-1α, IL-12p40 (at median), IL-3 and IL-5 (as
>0) were dichotomized to better fit in the model. None of the
analyzed cytokines from either cohort reached significance (p <
0.0038) with regard to subtype membership prediction except for
BDNF in the Toronto cohort (p < 0.003), which could not be
confirmed in the Tübingen cohort. Some other cytokines showed
a tendency (p < 0.05) for group separation. In some markers, a
significant confounding effect of age or LEDD (not gender and
disease duration) was detected which was inconsistent between
cohorts. Comparison of the results in both cohorts is presented
in Supplementary Table 3.
Out of all cytokines analyzed, only IL-12p40 showed a
trend toward significance in both cohorts for distinguishing
the “Benign motor” from the “Poor motor with cognitive
impairment” group (Method-4, Supplementary Table 3). In the
Tübingen cohort, lower values of IL-12p40 were associated with
the “Poor motor with cognitive impairment” group against
“Benign motor” group independent from the effects of age, sex,
disease duration, and LEDD [Nagelkerke R2 23%, B = −3.8, p
= 0.03, Exp(B) = 0.02]. Likewise, the Toronto cohort showed
that individuals with a high IL-12p40 value were less likely to be
in the “Poor motor with cognitive impairment” group compared
to the “Benign motor” group [Nagelkerke R2=35%, B = −2.16,
p = 0.02, Exp(B) = 0.12] (Supplementary Figure 1). Details of
logistic regression results of other cytokines are given in the
Supplementary Table 4.
[18F] FEPPA-PET Imaging
A [18F] FEPPA-PET imaging from 8 regions of brain was
performed for IL12-p40, since it was the only (trend toward
an) effect that could be replicated in the second cohort.
Eighteen participants from Toronto were divided into two
groups according to the lower and upper half of IL-12p40
values. Individuals in both groups showed a mixture of clinical
phenotypes. No significant difference was detected between
individuals with high or low values of IL-12p40 regarding the
microglial activation from different regions of the brain (p >
0.10) (Figure 2). Details of the statistical analysis of brain regions
are shown in Supplementary Table 5.
DISCUSSION
In this study, we compared serum immune markers in PD
patients with different clinical subtypes in two independent
cohorts. The results show that our assessment of serum immune
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FIGURE 1 | Score plot of the component values of individual inflammatory markers in PCA.
markers, based on the current state of the art of technology, does
not sufficiently discriminate clinical subgroups of PD.
Assessing immune marker levels in blood is easily accessible,
and therefore has been frequently used to investigate the
differences between PD patients and healthy controls. Although
there are variations in study design, analysis technology, and
findings in these studies (19), peripheral levels of some immune
markers seem to be increased in PD patients indicating an
ongoing inflammatory process that may trigger or at least
accompany neurodegeneration (19). Some of these studies
additionally investigated correlations between marker levels and
several clinical characteristics such as motor worsening, disease
severity, and non-motor status (20–23). Although the results are
inconclusive, a further question was raised whether a substantial
increase in already existing inflammation may be associated
with non-motor features such as autonomic disturbances or
dementia. To date, few studies have focused on relationships
with non-motor features as the primary outcome. In a 3-
year longitudinal study, William-Gray et al. reported that a
pro-inflammatory immune marker profile predicted disease
progression and correlated with Mini-Mental State Examination
scores (24). In another study, Brockmann et al. separated PD
patients with LRRK2mutations according to the presence of non-
motor symptoms and found that some pro-inflammatory marker
levels were higher in the subgroup with a greater non-motor
burden (16).
Contrary to these results, we failed to find an association
with these disease specific features. Although some markers
showed a trend (p < 0.05), no clear finding could be extracted
from the results of both cohorts for separating subtypes. On
this basis, it can be argued that a direct or linear association
between serum marker levels and symptom profile is unlikely in
a complex disorder like PD, which is comprised of a variety of
motor, autonomic, cognitive, psychiatric, and sensory symptoms
from distinct domains with different onset and progression
rates. Besides, studies investigating immune markers in blood
samples for a relatively regional neurodegeneration of the central
nervous system have important limitations. For example, these
immune markers are not specific for neuroinflammation and
a co-existing systemic inflammation/infection should be taken
into account which was considered only in few of the studies
(22, 24). Perhaps even a subclinical infection which cannot be
easily ruled out could compromise the results. In our study,
we have excluded patients with CRP >1.0 mg/dl at least to
rule out clinically relevant infections, but we can still not be
entirely sure whether the results were biased by an unknown
systemic or regional inflammatory process. Therefore, even if an
increase in serum immune markers was detected, this increase
may not be indicative of neuroinflammation related to the CNS
pathogenesis of PD but rather another overlapping comorbidity
such as a metabolic syndrome, rheumatic disease, or another
accompanying inflammatory process (e.g., via dysphagia and
consecutive subtle pulmonary infection, via urinary symptoms
with consecutive infection) secondary to PD since these patients
are relatively prone to systemic infections (25).
Immune markers may also have both pro- and anti-
inflammatory functions according to the stage of inflammation.
Accumulating evidence shows that some of the cytokines, even
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FIGURE 2 | Graphs of partial volume effect corrected (PVEC) total distribution volume (VT ) in different brain regions in individuals with higher or lower IL-12p40 values.
the well-known pro-inflammatory cytokines such as TNF-α,
IFN-δ, or IL-6 may have a dual function (26–29), which supports
the idea that functional distinction of cytokines as pro- or anti-
inflammatory is too simplistic and may not adequately describe
the actual inflammatory landscape (30). In our study, we found a
trend for IL-12p40 to be decreased in more affected PD patients
in both cohorts. This result is in line with recent literature
about IL-12p40 in Alzheimer disease (31). Alternatively, although
IL-12p40 is primarily a pro-inflammatory marker, it can also
stimulate an immunosuppressive response when only slightly
increased (32), supporting the dual-function hypothesis. This
dual function of the cytokines may have prevented the clear
separation of factor loadings in our PCA analysis which was
also observed in William-Gray et al. (24). In both studies, the
component with a pro-inflammatory profile also included anti-
inflammatory cytokines indicating that these immune markers
act closely in a complex network and cannot be used to determine
a PD subgroup.
The levels of serum immune markers are also affected by a
variety of factors such as nutrition (33), body mass index (34),
sleep (35), smoking (36), thyroid hormone levels (37), exercise
(38, 39), drinking coffee (40, 41), frailty (42), or depression
(43, 44), and thus can be considered to be non-specific. These
factors could have contributed to the negative outcome of this
study. They may also explain the controversial literature that
exists for levels of IL-15 (45, 46), IL-6 (47–49), TNF-α (49, 50),
IL-10 (32, 51) in association with PD occurrence, TNF-α in
association with cognitive scores (20, 52), and IL-6 with UPDRS
(24, 53), cognition (20, 54), and depression scores (22, 48) in
PD patients. Similarly, results are also conflicting in Alzheimer’s
disease (55). Considering that all these factors that can hardly be
controlled, results from such studies should be interpreted with
appropriate caution.
Moreover, intrinsic factors such as treatment and disease
progression may contribute to the high variability of immune
markers. Little is known about the effect of antiparkinsonian
treatment on ongoing inflammation. Several reports have shown
that dopamine may have some effect on the immune response
(56, 57). Based on these findings, the effect of treatment on
immune markers was investigated in some studies (45, 46) or
has been taken into account by adding LEDD in the regression
model as a confounder (including our study), but not all studies
have done this (20, 52). Furthermore, over the course of the
progressive disease, the inflammation rate and therefore the
blood level of markers may vary since the inflammatory response
may modify itself due to the changes in the amount of cells
alive, receptor count, or accumulation of α-syn (58). Diversity
in the inflammatory response in different brain regions, and
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up/downregulations in mRNA expression of pro-inflammatory
markers between early and late Braak stages have been
demonstrated (59). Besides, activation of microglia by α-syn may
result in upregulation of both toxic and neuroprotective
activity of the microglia (60), further contributing to
the limitations in the interpretation of immune markers
in PD.
Limitations of the current study have to be mentioned.
Eliminating patients with a serum CRP level >1 may have
affected our results i.e., may party explain the non-significant
results. The serum levels of other positive or negative acute-phase
proteins such as procalcitonin, alpha-1 antitrypsin, albumin,
or ferritin could also have been alternatively considered for
a better detection of individuals with an acute infection.
Moreover, we have only considered age, sex, disease duration,
and LEDD as potential confounders. Other above mentioned
factors such as body mass index, exercise, sleep, smoking, anti-
inflammatory drug usage as well as potential comorbidities
such as rheumatic or cardiovascular diseases were not taken
into account. The possible distortion of results during the
transport of frozen blood samples from Toronto and the cross-
sectional study-design are also limitations. On the other hand,
comparison of the findings in two independent and prospectively
assessed cohorts, and although with a small sample, PET
imaging are the strengths of the present study. Considering
the lack of convincing associations in either cohort, and
considering the ambiguous results from previous literature, we
conclude that immune mechanisms in PD are far more complex
than previously thought. Future longitudinal studies should
include strictly designed grouping and confounder assessments
to reveal whether specific inflammatory backgrounds are
associated with and potentially account for clinical diversity
in PD.
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